Related Experiment Video
Updated: Nov 10, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes
Christina M Bebber1,2,3, Emily S Thomas1,2,4, Jenny Stroh1,2
1Department of Translational Genomics, Medical Faculty, University of Cologne, Cologne, Germany.
Abstract:
Loss of TP53 and RB1 in treatment-naïve small cell lung cancer (SCLC) suggests selective pressure to inactivate cell death pathways prior to therapy. Yet, which of these pathways remain available in treatment-naïve SCLC is unknown. Here, through systemic analysis of cell death pathway availability in treatment-naïve SCLC, we identify non-neuroendocrine (NE) SCLC to be vulnerable to ferroptosis through subtype-specific lipidome remodeling. While NE SCLC is ferroptosis resistant, it acquires selective addiction to the TRX anti-oxidant pathway. In experimental settings of non-NE/NE intratumoral heterogeneity, non-NE or NE populations are selectively depleted by ferroptosis or TRX pathway inhibition, respectively. Preventing subtype plasticity observed under single pathway targeting, combined treatment kills established non-NE and NE tumors in xenografts, genetically engineered mouse models of SCLC and patient-derived cells, and identifies a patient subset with drastically improved overall survival. These findings reveal cell death pathway mining as a means to identify rational combination therapies for SCLC.
Insights
Small cell lung cancer (SCLC) cells lacking TP53 and RB1 pathways have specific vulnerabilities. Targeting ferroptosis in non-neuroendocrine (NE) SCLC and the TRX pathway in NE SCLC, combined, effectively treats tumors.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Cell Death Mechanisms
Background:
- Small cell lung cancer (SCLC) frequently exhibits loss of TP53 and RB1 tumor suppressors, indicating a need to evade cell death before treatment.
- The specific cell death pathways available or inactivated in treatment-naïve SCLC remain largely uncharacterized.
Purpose of the Study:
- To systematically analyze cell death pathway availability in treatment-naïve SCLC.
- To identify vulnerabilities and potential therapeutic targets based on SCLC subtype-specific mechanisms.
Main Methods:
- Systemic analysis of cell death pathway availability in treatment-naïve SCLC models.
- Lipidome remodeling analysis to assess ferroptosis vulnerability.
- Experimental models including xenografts, genetically engineered mouse models, and patient-derived cells to test combination therapies.
Main Results:
- Non-neuroendocrine (NE) SCLC is susceptible to ferroptosis due to subtype-specific lipidome remodeling.
- Neuroendocrine (NE) SCLC is resistant to ferroptosis but depends on the TRX anti-oxidant pathway.
- Combined targeting of ferroptosis and TRX pathways overcomes subtype plasticity and eradicates established tumors in preclinical models.
Conclusions:
- Cell death pathway mining reveals distinct vulnerabilities in non-NE and NE SCLC subtypes.
- Combination therapy targeting both ferroptosis and TRX pathways demonstrates significant efficacy against heterogeneous SCLC.
- These findings support a strategy of targeting cell death pathways for rational combination therapy development in SCLC.
